Eli Lilly said its investigational drug retatrutide was more effective at lowering blood sugar and reducing weight than Novo Nordisk’s Ozempic in a large diabetes study, according to STAT. The announcement positions Lilly as a strong competitor in the diabetes treatment market.
For pharma executives, this signals a shift in the competitive field for diabetes therapies. The result could influence future regulatory reviews, payer decisions and market share in a major therapeutic area.
